- Pfizer's (NYSE:PFE) announcement yesterday of an $10B stock repurchase plan deflates expectations that it will make another run at AstraZeneca (NYSE:AZN). Under British takeover rules, it could do so in November. In any event, the change in U.S. tax regulations making inversions less attractive makes a mega-deal like this unlikely.